RADNOR, Pa., Dec. 5, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom...
NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their...
LOS ANGELES, Dec. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...
NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as
RADNOR, Pa., Nov. 17, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom...
NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
NEW YORK, Nov. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment....
NEW YORK, Nov. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the...
(NASDAQ:DXCM) NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, DexCom insiders...
(NASDAQ:DXCM) SAN DIEGO & BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabetes Day (Nov. 14) and beyond. Now through Sept. 19, people from 2 years and older living with all types of diabetes and
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025 at 2:15 pm (EDT) The Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 2:00 pm (EDT) Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for futur
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, today released its Dexcom State of Type 2 Report: Access and Attitudes Across the United States ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States. During the conference, Dexcom will p
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purpo
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...
Dexcom G7 15-Day CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features.
Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.
DexCom (NASDAQ:DXCM) has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion.
